BRAF V600E mutation in papillary thyroid cancer is correlated with adverse clinicopathological features but not with iodine exposure

Creative Commons License

Ozcelik S., Bircan R., Sarikaya S., Gul A. E., Aydin B., Ozcelik M., ...More

ENDOKRYNOLOGIA POLSKA, vol.70, pp.401-408, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 70
  • Publication Date: 2019
  • Doi Number: 10.5603/ep.a2019.0025
  • Journal Name: ENDOKRYNOLOGIA POLSKA
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.401-408
  • Keywords: papillary thyroid cancer, BRAF V600E, iodine, BRAF V600E MUTATION, BRAF(V600E) MUTATION, PREVALENCE, CARCINOMA, ASSOCIATION, RECURRENCE, GENE
  • Marmara University Affiliated: Yes

Abstract

Introduction: BRAF(V600E) activating mutation is the most frequent genetic abnormality in the pathogenesis of papillary thyroid carcinoma. We aimed to evaluate the association between BRAF(V600E )mutation and well-established prognostic clinicopathological characteristics as well as iodine exposure.